Alx Oncology Holdings Inc

NASDAQ:ALXO  
29.38
-1.63 (-5.26%)
Products, Regulatory

ALX Oncology Announces Updated Data From Ongoing Clinical Trial (ASPEN-01) Of Evorpacept

Published: 11/09/2021 12:41 GMT
Alx Oncology Holdings Inc (ALXO) - Alx Oncology Announces Updated Data From Ongoing Clinical Trial (aspen-01) of Evorpacept Showing Emerging Clinical Benefit in Survival-based Endpoints in Patients With Advanced Solid Tumors.
Alx Oncology Holdings Inc - 12-month Os Rate of 87.5% and Mos Not Reached in Patients With 1l Head and Neck Cancer.
Alx Oncology Holdings Inc - 12-month Os Rate of 80% and Mos of 24.5 Months in Patients With Checkpoint NaÏve >2l Head and Neck Cancer.
Alx Oncology - Prelim Data Suggest Evorpacept Well Tolerated With Multi-agent Chemotherapy Regimens Studied With No Maximum Tolerated Dose Reached.